An Absolute Bioavailability Study of LY3039478 in Healthy Subjects Using the Intravenous Tracer Method
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Crenigacestat (Primary)
- Indications Acute lymphoblastic leukaemia; Leukaemia; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 24 Jan 2017 Status changed from recruiting to completed.
- 06 Oct 2016 Status changed from not yet recruiting to recruiting.
- 29 Sep 2016 New trial record